uniQure NV led investors to believe it would garner accelerated regulatory approval for its treatment of a neurodegenerative disease before casting doubt on its application timeline, a proposed class action said.
uniQure’s touting of topline results for its study in September caused the stock price to pop, but it soon crashed on news the Food and Drug Administration didn’t find the clinical data sufficient to be the backbone of its biologics license application, said the complaint filed Tuesday.
The gene therapy company followed the share price jump with a public offering, reaping $345 million in proceeds while misrepresenting its application ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.